Seeking Alpha

Teva (TEVA) will be able to launch a generic version of Gilead's (GILD) Viread treatment for HIV...

Teva (TEVA) will be able to launch a generic version of Gilead's (GILD) Viread treatment for HIV and chronic hepatitis B in December 2017 after the companies reached a settlement ahead of a trial that was due to begin today. Gilead sued Teva in 2008 and 2010 for infringing its patents after the latter applied to the FDA to manufacture the drugs. Teva said the patents were invalid. (PR)
Comments (1)
  • doc47
    , contributor
    Comments (1119) | Send Message
     
    And the market reaction is (drum roll please)... _15 cents on the day!!!
    Better luck next time!
    20 Feb 2013, 04:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector